The global cardiac biomarkers market size was valued at USD 26.5 billion in 2025 and is projected to grow from USD 30.24 billion in 2026 to USD 86.86 billion by 2034, registering a CAGR of 14.1% during the forecast period from 2026 to 2034. North America dominated the cardiac biomarkers market with a market share of 39.2% in 2025.
Cardiac biomarkers are enzymes, proteins, and hormones released into the bloodstream during heart damage, helping to detect conditions such as myocardial infarction. The rising demand for point-of-care (POC) cardiac testing kits, valued for their fast and accurate results, is accelerating market growth. Technological integration, including AI and machine learning, enhances diagnostic precision, monitoring, and interpretation, further supporting adoption. Cardiac test kits with multi-parameter panels enable the rapid detection of abnormalities, reduce diagnostic delays, and enhance clinical decision-making in emergencies. Overall, fast diagnostics and advanced technologies continue to drive the market.
Download a Free Sample To learn more about this report,
Integration of Artificial Intelligence With Cardiac Biomarker Analysis
The complexity of cardiovascular diagnosis and the growing volume of biomarker and clinical data are encouraging researchers to integrate artificial intelligence with cardiac biomarker analysis. This transition is supporting the combined interpretation of biomarkers such as high-sensitivity cardiac troponin with ECG and other clinical information, helping improve risk assessment and diagnostic decision-making. For example, a 2026 systematic review reported that a machine-learning model integrating age, sex, ECG, clinical information, and high-sensitivity troponin achieved an AUROC of 93% for predicting 30-day myocardial infarction or death in 40,312 patients with chest pain.
Development of Multiplex Cardiac Biomarker Panels
The need to capture different biological processes involved in cardiovascular disease is encouraging the development of panels that measure multiple cardiac biomarkers from a single patient sample. This transition is providing a broader view of myocardial injury, inflammation, and cardiac stress, supporting more comprehensive risk assessment than reliance on a single biomarker. For example, a study of 891 patients with heart failure evaluated a panel containing NT-proBNP, high-sensitivity troponin T, and ST2 for predicting recurrent hospitalizations.
Rapid Cardiac Diagnosis and High-Sensitivity Testing Drive Market
The need for rapid assessment of suspected cardiac events creates requirements for biomarkers that provide timely evidence of myocardial injury. The American College of Cardiology identifies high-sensitivity cardiac troponin as the preferred biomarker for detecting myocardial injury and notes that rapid testing can expedite evaluation of patients with suspected acute coronary syndrome. For example, emergency departments can use cardiac troponin testing for patients arriving with chest pain to support decisions on further evaluation and treatment. This clinical requirement supports regular use of cardiac biomarker assays and continued supply of compatible testing systems.
The need for earlier detection of myocardial injury creates requirements for high-sensitivity cardiac troponin assays that can measure very low concentrations of troponin. ACC guidance states that high-sensitivity troponin assays use an assay-specific 99th-percentile upper reference limit and can support rapid clinical decision pathways for suspected acute coronary syndrome. FDA records also show multiple cleared high-sensitivity troponin assays, including the atellica im high-sensitivity troponin i assay cleared in 2024. This clinical adoption supports procurement of high-sensitivity analyzers, reagents, and cardiac biomarker testing supplies.
Limited access to advanced diagnostic infrastructure can restrict the availability of cardiac biomarker testing in healthcare facilities without automated analyzers, specialized laboratories, and reliable laboratory networks. WHO reports that access to diagnostics remains limited in many low- and middle-income settings and identifies infrastructure and laboratory capacity as key requirements for effective diagnostic services. These infrastructure gaps can reduce testing capacity and accessibility, slowing the adoption and market growth of advanced cardiac biomarker technologies.
Complex interpretation of biomarker results can arise because cardiac biomarker levels may be influenced by factors such as kidney dysfunction, age, chronic conditions, and other clinical conditions. Such cases can require additional clinical assessment and diagnostic testing to distinguish acute cardiac injury from other causes of elevated biomarker levels. This interpretive complexity can reduce confidence in standalone biomarker testing and slow the wider adoption of cardiac biomarker technologies.
Cardiac biomarker developers, pharmaceutical companies, diagnostic laboratories, and clinical research organizations can collaborate on biomarker validation and cardiovascular drug development. Roche evaluates cardiovascular biomarker opportunities with universities, research institutes, and biotechnology companies, creating revenue through licensing, testing services, and co-development programs.
Diagnostic companies, healthcare providers, insurers, and preventive-care platforms can incorporate cardiac biomarker testing into routine cardiovascular risk assessments. Labcorp offers cardiovascular testing that includes hs-CRP, NT-proBNP, BNP, and high-sensitivity troponin, creating revenue through recurring screening and laboratory services.
Biomarker concentrations can vary with factors such as age, sex, kidney function, underlying disease, and timing of sample collection. The American Heart Association notes that high-sensitivity cardiac troponin concentrations can be influenced by age, sex, renal function, and other clinical factors, which need to be considered when interpreting results. Such biological variation can complicate assay validation across patient populations and increase development requirements for new cardiac biomarker tests.
Biomarker developers require diverse, well-annotated patient samples to establish assay performance and clinical utility. The National Cancer Institute's biobank guidance notes that high-quality biospecimens and associated clinical data are essential for reliable biomarker research, while differences in collection, processing, and storage can affect specimen quality. Limited access to consistently characterized clinical samples can therefore slow validation and increase development costs for cardiac biomarker companies.
The troponins (T and I) segment accounted for a 48.7% share in 2025 and is expected to grow at a CAGR of 13.2% during the forecast period 2026-2034, driven by their high clinical sensitivity and specificity for detecting myocardial injury, increasing demand for early diagnosis of acute coronary syndromes, and widespread adoption in emergency and hospital settings. the growing prevalence of cardiovascular diseases, increasing use of high-sensitivity troponin assays, and advances in cardiac diagnostic technologies further strengthen the segment’s dominant position in the cardiac biomarkers market.
The myocardial muscle creatine kinase (CK-MB) segment supports cardiac injury assessment, particularly when evaluating myocardial damage alongside other diagnostic markers. the myoglobin segment contributes through its rapid response to muscle injury, while the others segment includes additional cardiac biomarkers used for cardiovascular risk assessment, disease detection, and clinical monitoring.
Request Customizationto receive a tailored report.
The myocardial infarction segment accounted for a share of 37.8% in 2025, owing to the widespread use of cardiac biomarkers for detecting myocardial injury, increasing prevalence of heart attacks, and growing demand for rapid and accurate diagnosis. the increasing adoption of high-sensitivity biomarker testing, rising awareness of early cardiac diagnosis, and expanding emergency cardiac care further strengthen the segment’s dominant position in the cardiac biomarkers market.
The congestive heart failure segment is expected to grow at a CAGR of 13.5% during the forecast period, driven by increasing prevalence of heart failure, growing demand for early disease detection and monitoring, and rising adoption of cardiac biomarker testing in clinical settings. the acute coronary syndrome segment supports rapid assessment of patients with suspected cardiac ischemia, while the others segment includes additional applications of cardiac biomarkers across cardiovascular disease diagnosis, risk assessment, and patient monitoring.
The laboratory testing segment accounted for a share of 57.4% in 2025 due to the widespread use of laboratory-based cardiac biomarker testing, availability of advanced diagnostic equipment, and established laboratory infrastructure across healthcare facilities. the increasing volume of cardiovascular diagnostic testing, growing demand for accurate biomarker analysis, and continued adoption of automated laboratory technologies further strengthen the segment’s dominant position in the cardiac biomarkers market.
The point of care testing segment is expected to grow at a CAGR of 14.3% during the forecast period, fueled by increasing demand for rapid cardiac disease diagnosis, growing adoption of decentralized testing, and rising need for immediate clinical decision-making in emergency and acute care settings. the portability of point-of-care systems, shorter testing times, and expanding use in emergency departments and ambulatory settings further support growth of the segment. the others segment includes additional testing environments and diagnostic settings that contribute to cardiac biomarker analysis.
Speak to an Analystto discuss market opportunities.
The North America cardiac biomarkers market accounted for the largest regional share of 39.2% in 2025, driven by advanced cardiac diagnostic infrastructure, high adoption of biomarker-based testing, and increasing demand for early detection of cardiovascular diseases. The U.S. cardiac biomarkers market is supported by continued adoption of cardiac troponin testing for cardiovascular diagnosis and risk assessment. High-sensitivity cardiac troponin assays are used for earlier detection of myocardial injury, while recent U.S. research continues to evaluate their role in cardiovascular disease risk prediction and clinical decision-making.
The Canada cardiac biomarkers market is supported by continued use of cardiac biomarkers in cardiovascular research and clinical trials. The Canadian Clinical Trial Search Portal includes studies evaluating NT-proBNP and cardiac troponin T in patients with heart failure, demonstrating ongoing clinical research involving cardiac biomarkers in Canada.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific cardiac biomarkers market is expected to grow at a CAGR of 14.7%, showcasing the fastest-growing regional market, driven by rising cardiovascular disease prevalence, expanding healthcare infrastructure, and increasing adoption of advanced diagnostic technologies. In Japan, the Japan agency for medical research and development (AMED) reported in August 2026 that its CANNDs multi-omics database added single-nucleus RNA sequencing data from heart-failure cardiac tissue. The platform also includes multi-omics datasets covering cardiovascular diseases, supporting research into molecular mechanisms and potential biomarkers for cardiovascular conditions. In China, the national cardiovascular center commissioned analysis of cardiovascular disease metabolic biomarkers using mass spectrometry under its major chronic-disease prevention project in May 2026. The procurement specifically involved testing and analysis of metabolic biomarkers associated with cardiovascular diseases, providing direct evidence of investment in cardiovascular biomarker research and analytical technologies.
In South Korea, national health and biomedical research programs continue to support cardiovascular disease research and biomarker development, although a specific 2026 government or institutional project directly focused on cardiac biomarkers would provide stronger evidence for market-specific analysis. In India, the indian council of medical research (ICMR) has an established research program titled “development of biomarkers for cardiovascular diseases & diabetes,” with official research documentation available through its programs and publications. ICMR’s cardiovascular guidance also identifies BNP/NT-proBNP and troponin among desirable investigations for cardiovascular disease assessment, providing evidence of the clinical use of cardiac biomarkers in India.
The Europe cardiac biomarkers market accounted for a regional share of 28.1% in 2025, supported by strong healthcare systems, increasing demand for early cardiovascular disease detection, and growing adoption of advanced laboratory diagnostics. In the U.K. cardiac biomarkers market, NHS England’s 2026/27 guidance recommends NT-proBNP testing for people with suspected heart failure, with raised results triggering echocardiography and specialist assessment within specified timeframes. This continued integration of natriuretic peptide testing into clinical pathways supports demand for cardiac biomarker diagnostics.
In the Germany cardiac biomarkers market, cardiovascular diseases remain the leading cause of death, accounting for approximately 40% of all deaths in the country, according to the Robert Koch Institute in June 2026. The substantial cardiovascular disease burden supports continued demand for diagnostic testing and biomarkers used in cardiovascular assessment. Meanwhile, the France cardiac biomarkers market is supported by a substantial cardiovascular disease burden, with the Ministry of Health reporting in May 2026 that more than 15 million people in France were treated for cardiovascular disease, cardiovascular risk, or diabetes, while cardiovascular diseases remained the country's second-leading cause of death. The emphasis on cardiovascular prevention and care supports continued demand for diagnostic tools, including cardiac biomarkers.
The Middle East and Africa cardiac biomarkers market is expected to grow at a CAGR of 11.5%, supported by improving diagnostic infrastructure, rising awareness of cardiovascular health, and increasing investments in advanced healthcare technologies. The UAE cardiac biomarkers market is expected to benefit from Abu Dhabi’s increasing focus on precision medicine, early disease detection, and cardiovascular research. The department of health – Abu Dhabi’s 2026 healthcare research and innovation fund identifies metabolic and cardiovascular conditions, precision medicine, omics-driven diagnostics, and early disease detection as priority areas, supporting future demand for advanced diagnostic technologies such as cardiac biomarker testing.
The Africa cardiac biomarkers market is expected to benefit from expanding cardiovascular diagnosis and laboratory capacity. In 2026, WHO’s pen-plus strategy focused on improving access to diagnosis and treatment for severe noncommunicable diseases across Africa, including rheumatic and congenital heart diseases, while its regional diagnostic strategy targets accessible, quality-assured diagnostic services across member states by 2032. These initiatives are expected to support wider adoption of cardiovascular diagnostic technologies, including cardiac biomarker testing.
The cardiac biomarkers market is moderately fragmented, with diagnostic companies, biotechnology firms, pharmaceutical companies, medical device manufacturers, clinical laboratory providers, and specialized biomarker technology companies competing across cardiovascular diagnostics, risk assessment, disease monitoring, and clinical research applications. Established players compete primarily on diagnostic accuracy, biomarker sensitivity and specificity, technological innovation, assay performance, product reliability, regulatory compliance, research and development capabilities, test menu breadth, automation, clinical validation, and global distribution networks, with leading players such as roche diagnostics, abbott laboratories, siemens healthineers, beckman coulter (danaher corporation), and thermo fisher scientific estimated to account for approximately 55% of the global market based on their diagnostic portfolios, technological capabilities, geographic presence, and competitive positioning.
Emerging and regional players within the cardiac biomarkers market ecosystem compete through cost-effective testing solutions, rapid diagnostic technologies, specialized biomarker assays, point-of-care platforms, customized solutions, flexible manufacturing, localized support, and application-specific products to address evolving cardiovascular diagnostic requirements and strengthen their market presence. These players also focus on developing innovative biomarker assays, improving testing accessibility, and expanding specialized diagnostic capabilities to differentiate their offerings and broaden their market reach.
The global cardiac biomarkers market is moderately consolidated, with leading diagnostics, healthcare, and life sciences companies competing through continuous product innovation, strategic partnerships, advanced immunoassay technologies, and investments in cardiovascular diagnostic solutions. The major players in the market include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Ortho Clinical Diagnostics, Beckman Coulter (Danaher Corporation), Thermo Fisher Scientific, BioMérieux, SeraCare Life Sciences, Randox Laboratories, and Quidel Corporation.
Industry participants are increasingly focusing on developing high-sensitivity cardiac biomarker assays, automated immunoassay platforms, point-of-care testing solutions, and multiplex diagnostic technologies to support the early detection and risk assessment of cardiovascular conditions. Companies are also investing in advanced troponin testing, biomarker standardization, laboratory automation, rapid testing platforms, and digital diagnostic technologies while expanding collaborations with hospitals, clinical laboratories, and healthcare providers to improve diagnostic accuracy and enable faster clinical decision-making.
ACS Biomarker B.V. has emerged as a prominent player in the cardiac biomarkers market through its focus on biomarker research, assay development, and diagnostic solutions designed to support cardiovascular disease assessment. The company continues to strengthen its market presence by developing specialized biomarker technologies and analytical solutions that support research and clinical applications in cardiovascular health.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Tejas Zamde is a market research professional with over 2 years of experience in the technology, semiconductor, electronics, and automotive sectors. He specializes in market assessment, competitive intelligence, industry analysis, market sizing, demand analysis, and strategic research.
His experience includes analyzing technology trends, market dynamics, regulatory developments, supply-demand patterns, value chains, and competitive landscapes across global and regional markets. He has supported clients with opportunity assessment, customer segmentation, competitive benchmarking, and growth strategy development.
Consumer Electronics Market Size, Share, Growth, Analysis, 2034
Light Detection and Ranging Market Size, Forecast, Demand, Opportunities, 2034
Bioelectric Medicine Market Size, Share, Growth, Analysis, 2034
PCB Design Software Market Size, Share, Growth, 2034
Printed Circuit Board Market Size, Share, Growth, 2034
Sensor Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com